The approximate occurrence of VTE in users of oral contraceptives with low oestrogen content

Combined oral contraceptives (COCs) should not be used in the presence of any of the conditions listed below. Should any of the conditions appear during COC use, the product should be stopped immediately.  Thrombophlebitis or thromboembolic disorders  Presence or history of venous thrombosis (deep venous thrombosis, pulmonary embolism)  Presence or history of arterial thrombosis (myocardial infarction, cerebrovascular accident) or prodromal conditions (e.g. transient ischaemic attack, angina pectoris).  History of migraine with focal neurological symptoms  Known predisposition for venous or arterial thrombosis, such as Activated Protein C (APC) resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia and antiphospholipid antibodies  Valvular heart disease with complications  Severe hypertension (persistent systolic values of 160+ or persistent diastolic values of 100+ mm Hg)  Diabetes mellitus with vascular involvement.  The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis may also constitute a contraindication (see under ‘Special Warnings and Special Precautions for Use’).  Presence or history of severe hepatic disease as long as liver function values have not returned to normal.  Presence or history of liver tumours (benign or malignant).  Known or suspected malignant conditions of the genital organs or the breasts, if sex steroidinfluenced.  Endometrial hyperplasia.  Undiagnosed vaginal bleeding.  Cholestatic jaundice of pregnancy or jaundice with prior pill use  Known or suspected pregnancy.  Hypersensitivity to any of the active substances of Cilest or to any of the excipients.